General
Preferred name
rasagiline
Synonyms
RASAGILINE MESYLATE ()
AGN1135 (mesylate) ()
AGN1135 ()
TVP1012 ()
AZILECT ()
RASAGILINE MESILATE ()
Rasagiline (mesylate) ()
(R)-AGN1135 (mesylate) ()
TVP1012 (mesylate) ()
(R)-AGN1135 ()
TVP-1012,(R)-AGN1135 mesylate,TVP1012 mesylate ()
TVP-1012 ()
RASAGILINE TARTRATE ()
Rasagline ratiopharm ()
Rasagiline (as mesilate) ()
Rasagiline ratiopharm ()
Agilect ()
Rasagiline mesylate ()
AGN-1135 ()
Rasagilina ()
TV-1030 ()
NSC-759639 ()
Rasagiline-13C3 (mesylate) ()
Rasagiline hemitartrate ()
Rasagiline mylan ()
P&D ID
PD009528
CAS
161735-79-1
136236-51-6
1204184-69-9
1391052-18-8
Tags
available
covalent binder
drug
Approved by
EMA
PMDA
FDA
First approval
2016
2005
Drug indication
Skin imperfections
Skin cancer
multiple system atrophy
Restless legs syndrome
Parkinson disease
Drug Status
approved
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PRICE
29
DESCRIPTION
Rasagiline (R-AGN1135) is a highly potent selective irreversible mitochondrial monoamine oxidase (MAO) inhibitor with IC50s of 4.43 nM and 412 nM for rat brain MAO B and A activity, respectively[1]. Rasagiline is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
PRICE
29
DESCRIPTION
Selective inhibitor of myosin light chain kinase
(Tocris Bioactive Compound Library)
DESCRIPTION
Selective, irreversible MAO-B inhibitor
(Tocriscreen Plus)
DESCRIPTION
Rasagiline mesylate is an amine oxidase B inhibitor. It is used for the treatment of idiopathic Parkinson's disease.
(Enamine Bioactive Compounds)
DESCRIPTION
Rasagiline Mesylate (AGN1135) is a novel MAO-B inhibitor, which can treat idiopathic Parkinson's disease.
(TargetMol Bioactive Compound Library)
DESCRIPTION
Rasagiline (AGN1135) is an inhibitor of monamine oxidase used as adjunctive therapy in combination with levodopa and carbidopa in the management of Parkinsons disease.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
32
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Enamine Bioactive Compounds
Enamine BioReference Compounds
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
Mcule NIBR MoA Box Subset
NCATS Inxight Approved Drugs
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Other bioactive compounds
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Tocris Bioactive Compound Library
Tocriscreen Plus
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
75
Molecular Weight
171.1
Hydrogen Bond Acceptors
1
Hydrogen Bond Donors
1
Rotatable Bonds
2
Ring Count
2
Aromatic Ring Count
1
cLogP
1.9
TPSA
12.03
Fraction CSP3
0.33
Chiral centers
1.0
Largest ring
6.0
QED
0.67
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target Type
Enzymes
Pathway
Apoptosis
Metabolism
Neuroscience
Autophagy
Neuronal Signaling
Primary Target
Monoamine Oxidases
MOA
BCL inhibitor
Inhibitor
MAO-B Inhibitors
monoamine oxidase inhibitor
Member status
member
Target
BCL2, MAOB
Monoamine Oxidase
MAO
Bcl-2
MAO-A
MAO-B
Indication
Parkinson's Disease
Therapeutic Class
Antiparkinson Agents
Source data
